RxDoctor Payments Data

Toby Yaltho, MD

Neurology · Sugar Land, TXNPI 1033399837

Payments from drug & device makers

$270,890in general payments, 2019–2025

Across 1,410 payments — averaging $192.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$187K
  • MDD US Operations, LLC$42K
  • Acorda Therapeutics, Inc$14K
  • Sunovion Pharmaceuticals Inc.$10K
  • Amneal Pharmaceuticals LLC$1K
  • Acadia Pharmaceuticals Inc$1K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$4,5252%
  • Speaking & faculty fees$221,22188%
  • Travel & lodging$2,7671%
  • Food & beverage$23,7389%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)438$186,904
MDD US Operations, LLC87$42,442
Acorda Therapeutics, Inc38$13,822
Sunovion Pharmaceuticals Inc.14$10,389
Amneal Pharmaceuticals LLC40$1,424
Acadia Pharmaceuticals Inc79$1,192
SK Life Science, Inc.54$1,167
UCB, Inc.40$995
Amgen(2 entities)43$983
Novartis61$981
Boston Scientific14$808
Pfizer62$798
Abbott30$797
Neurocrine Biosciences, Inc.29$775
Teva Pharmaceuticals USA, Inc.52$728
EMD Serono, Inc.34$671
Biogen23$494
Lilly USA, LLC29$485
Argenx US, Inc.14$424
Medtronic(2 entities)6$421
Genentech USA, Inc.20$383
Eisai Inc.14$310
Harmony Biosciences LLC19$305
Takeda Pharmaceuticals U.S.A., Inc.11$274
Grifols USA, LLC12$262
Sanofi13$262
Lundbeck LLC13$250
Biohaven Pharmaceuticals, Inc.12$157
Merz Pharmaceuticals, LLC7$150
Biohaven Pharmaceutical Holding Company Ltd.9$144
Corium, LLC7$139
Kyowa Kirin, Inc.5$110
Supernus Pharmaceuticals, Inc.5$108
AstraZeneca(2 entities)4$106
Arbor Pharmaceuticals, Inc.6$93
Tanabe Pharma America, Inc.6$86
Neurelis, Inc.3$70
Upsher-smith Laboratories LLC4$69
Jazz Pharmaceuticals Inc.3$68
Johnson & Johnson(2 entities)3$63
GE HealthCare3$61
Almatica Pharma LLC3$59
Azurity Pharmaceuticals, Inc.3$55
Avadel CNS Pharmaceuticals, LLC2$54
Piramal Critical Care3$52
Vanda Pharmaceuticals Inc.3$49
Merz North America, Inc.2$43
Livanova USA, Inc.2$39
Impel Pharmaceuticals Inc.2$38
Assertio Therapeutics, Inc.2$36
Aucta Pharmaceuticals, Inc.8$33
Greenwich Biosciences, Inc.2$29
Averitas Pharma Inc.1$28
Avion Pharmaceuticals2$27
Catalyst Pharmaceuticals, Inc.1$26
TG Therapeutics, Inc.1$25
Ipsen Biopharmaceuticals, Inc1$25
Bausch Health US, LLC1$22
Vertical Pharmaceuticals, LLC1$20
Aquestive Therapeutics, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$270,890 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$362,569
Medicare patients
465
Services billed
29,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate47$378,647
RytaryCarbidopa/Levodopa191$328,061
IngrezzaValbenazine Tosylate23$189,345
GocovriAmantadine Hcl52$175,672
NeuproRotigotine28$39,393
Carbidopa-LevodopaCarbidopa/Levodopa713$23,790
Rasagiline Mesylate123$12,729
Rivastigmine45$11,103
Primidone192$10,894
Carbidopa-Levodopa ErCarbidopa/Levodopa188$10,120
Pramipexole ErPramipexole Di-Hcl25$8,648
Propranolol Hcl ErPropranolol Hcl178$8,248
Memantine Hcl196$5,814
Donepezil Hcl238$5,351
Propranolol Hcl145$4,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,192$378,64747 claims
Amneal Pharmaceuticals LLCRytary$1,424$328,061191 claims
Neurocrine Biosciences, Inc.Ingrezza$775$189,34523 claims
MDD US Operations, LLCGocovri$42,442$175,67252 claims
UCB, Inc.Neupro$995$39,39328 claims
Upsher-smith Laboratories LLCTopiramate$69$1,810116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →